Back to Blog
Keynote 5225/15/2023 After one and a half years, 72% of patients who had Keytruda were still disease-free compared with 54% of patients who had placebo.Īnother study compared Keytruda to placebo in 976 patients who had not received previous treatments and had surgery to remove their cancer. Also, up to 74% of patients treated with Keytruda lived for at least 12 months after the start of their treatment compared with 59% of patients on ipilimumab.Ī third study in 1,019 patients who had had surgery and who were at high risk for their cancer coming back compared Keytruda to placebo (a dummy treatment). Patients treated with Keytruda lived for up to 5.6 months without their disease getting worse compared with 2.8 months with ipilimumab. Results from a study of 540 previously treated patients with melanoma showed that 2 years after start of treatment, the disease had not worsened in 16% of patients treated with Keytruda compared with less than 1% of patients treated with chemotherapy.Ī second study looked at 834 patients with melanoma who received either Keytruda or another medicine, ipilimumab. Keytruda can delay worsening of melanoma and improve survival. Keytruda contains the active substance pembrolizumab. For the other cancers, Keytruda is only used on its own. It can be used on its own or in combination with other cancer medicines for NSCLC, HNSCC, endometrial carcinoma and renal cell carcinoma. In some patients with triple-negative breast cancer Keytruda can be given before (neoadjuvant treatment) and after ( adjuvant treatment) surgery. Keytruda is also used to help prevent the cancer from coming back after patients had surgery to remove melanoma or renal cell carcinoma ( adjuvant therapy).įor oesophageal cancer, cervical cancer and triple-negative breast cancer, Keytruda is used in combination with chemotherapy or other cancer medicines. In some cancers, it is only given to patients whose tumours produce certain levels of a protein known as PD-L1 or are determined to be as MSI-H or dMMR. Keytruda is also used in children aged 3 years and older with classical Hodgkin lymphoma, and in adolescents aged 12 years and older with melanoma. Keytruda is mainly used in adults for cancers that are advanced, have spread or returned, are not responding to other treatments or cannot be removed by surgery. gastric cancer (a cancer of the stomach), small intestine cancer, biliary cancer (a cancer of the bile ducts or gallbladder).colorectal cancer (a cancer of the colon or rectum, the lower part of the gut),.the following cancers described as microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) located in:.
0 Comments
Read More
Leave a Reply. |